Decreased numbers of CD57+CD3-cells identify potential innate immune differences in patients with autism spectrum disorder

In Vivo

Volumn 30, Issue 2, 2016, Pages 83-90

  Siniscalco, Dario ^a,b,c   Mijatovic, Tatjana ^d   Bosmans, Eugene ^d   Cirillo, Alessandra ^e   Kruzliak, Peter ^f,g   Lombardi, Vincent C ^h   De Meirleir, Kenny ⁱ   Antonucci, Nicola ^e  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Centre for Autism   (Italy)

^c Cancellautismo no profit association for autism care   (Italy)

^d R E D LABORATORIES   (Belgium)

^e Biomedical Centre for Autism Research and Treatment   (Italy)

^f MASARYK UNIVERSITY   (Czech Republic)

^g UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^h Nevada Center for Dermatology   (United States)

ⁱ Himmunitas Institute   (Belgium)

Author keywords

Autism; CD57+CD3 lymphocytes; HNK 1; Immune dysfunction

Indexed keywords

CD3 ANTIGEN; CD57 ANTIGEN; CYTOKINE; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; ARTICLE; AUTISM; CHILD; CHRONIC INFLAMMATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE DYSREGULATION; INNATE IMMUNITY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; CASE CONTROL STUDY; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIGENS, CD3; ANTIGENS, CD57; AUTISM SPECTRUM DISORDER; BIOMARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNITY, INNATE; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; YOUNG ADULT;

EID: 84978271617     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Siniscalco D, Cirillo A, Bradstreet JJ and Antonucci N: Epigenetic findings in autism: new perspectives for therapy. Int J Environ Res Public Health 10(9): 4261-4273, 2013.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, DC, USA: American Psychiatric Association; 2013.
3. Siniscalco D: Current Findings and Research Prospective in Autism Spectrum Disorders. Autism Open Access S2: e001, 2013.
4. Baio J: Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; Centers for Disease Control and Prevention (CDC) (2014). Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ 63: 1-21, 2014.
5. Siniscalco D: Endocannabinoid System as Novel Therapeutic Target for Autism Treatment. Autism Open Access 4: e122, 2014.
6. Bradstreet JJ, Smith S, Baral M and Rossignol DA: Biomarkerguided interventions of clinically relevant conditions associated with autism spectrum disorders and attention deficit hyperactivity disorder. Altern Med Rev 15(1): 15-32, 2010.
7. Voineagu I and Yoo HJ: Current progress and challenges in the search for autism biomarkers. Dis Markers 35(1): 55-65, 2013.
8. Siniscalco D: The searching for autism biomarkers: a commentary on: a new methodology of viewing extra-axial fluid and cortical abnormalities in children with autism via transcranial ultrasonography. Front Hum Neurosci 8: 240, 2014.
9. Zerbo O, Yoshida C, Grether JK, Van de Water J, Ashwood P, Delorenze GN, Hansen RL, Kharrazi M and Croen LA: Neonatal cytokines and chemokines and risk of Autism Spectrum Disorder: the Early Markers for Autism (EMA) study: a casecontrol study. J Neuroinflammation 11: 113, 2014.
10. Goldani AA, Downs SR, Widjaja F, Lawton B and Hendren RL: Biomarkers in autism. Front Psychiatry 5: 100, 2014.
11. Chadman KK: Making progress in autism drug discovery. Expert Opin Drug Discov 9(12): 1389-1391, 2014.
12. Shen MD, Nordahl CW, Young GS, Wootton-Gorges SL, Lee A, Liston SE, Harrington KR, Ozonoff S and Amaral DG: Early brain enlargement and elevated extra-axial fluid in infants who develop autism spectrum disorder. Brain 136(Pt 9): 2825-2835, 2013.
13. Bradstreet JJ, Pacini S and Ruggiero M: A New Methodology of Viewing Extra-Axial Fluid and Cortical Abnormalities in Children with Autism via Transcranial Ultrasonography. Front Hum Neurosci 7: 934, 2014.
14. Onore C, Careaga M and Ashwood P: The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun 26(3): 383-392, 2012.
15. Siniscalco D, Bradstreet JJ and Antonucci N: Therapeutic role of hematopoieticstem cells in autism spectrum disorder-related inflammation. Front Immunol 4: 140, 2013.
16. Siniscalco D, Sapone A, Giordano C, Cirillo A, de Novellis V, de Magistris L, Rossi F, Fasano A, Maione S and Antonucci N: The expression of caspases is enhanced in peripheral blood mononuclear cells of autism spectrum disorder patients. J Autism Dev Disord 42(7): 1403-1410, 2012.
17. Gesundheit B, Rosenzweig JP, Naor D, Lerer B, Zachor DA, Prochazka V, Melamed M, Kristt DA, Steinberg A, Shulman C, Hwang P, Koren G, Walfisch A, Passweg JR, Snowden JA, Tamouza R, Leboyer M, Farge-Bancel D and Ashwood P: Immunological and autoimmune considerations of Autism Spectrum Disorders. J Autoimmun 44: 1-7, 2013.
18. Le Belle JE, Sperry J, Ngo A, Ghochani Y, Laks DR, Lopez-Aranda M, Silva AJ and Kornblum HI: Maternal Inflammation Contributes to Brain Overgrowth and Autism-Associated Behaviors through Altered Redox Signaling in Stem and Progenitor Cells. Stem Cell Reports 3(5): 725-734, 2014.
19. Napoli E, Wong S, Hertz-Picciotto I and Giulivi C: Deficits in bioenergetics and impaired immune response in granulocytes from children with autism. Pediatrics 133(5): e1405-1410, 2014.
20. Samsam M, Ahangari R and Naser SA: Pathophysiology of autism spectrum disorders: revisiting gastrointestinal involvement and immune imbalance. World J Gastroenterol 20(29): 9942-9951, 2014.
21. Siniscalco D, Sapone A, Giordano C, Cirillo A, de Magistris L, Rossi F, Fasano A, Bradstreet JJ, Maione S and Antonucci N: Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. J Autism Dev Disord 43(11): 2686-2695, 2013.
22. Krueger DD and Brose N: Evidence for a common endocannabinoid-related pathomechanism in autism spectrum disorders. Neuron 78(3): 408-410, 2013.
23. Wang EC and Borysiewicz LK: The role of CD8, CD57 cells in human cytomegalovirus and other viral infections. Scand J Infect Dis 99: 69-77, 1995.
24. Yssel H, Shanafelt MC, Soderberg C, Schneider PV, Anzola J and Peltz G: Borrelia burgdorferi activates a T-helper type 1-like T-cell subset in Lyme arthritis. J Exp Med 174: 593-601, 1991.
25. Nielsen CM, White MJ, Goodier MR and Riley EM: Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease. Front Immunol 4: 422, 2013.
26. Warren RP, Foster A and Margaretten NC: Reduced natural killer cell activity in autism. J Am Acad Child Adolesc Psychiatry 26(3): 333-335, 1987.
27. Vojdani A, Mumper E, Granpeesheh D, Mielke L, Traver D, Bock K, Hirani K, Neubrander J, Woeller KN, O'Hara N, Usman A, Schneider C, Hebroni F, Berookhim J and McCandless J: Low natural killer cell cytotoxic activity in autism: the role of glutathione, IL2 and IL15. J Neuroimmunol 205(1-2): 148-154, 2008.
28. Becknell B and Caligiuri MA: Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 86: 209-239, 2005.
29. Enstrom AM, Lit L, Onore CE, Gregg JP, Hansen RL, Pessah IN, Hertz-Picciotto I, Van de Water JA, Sharp FR and Ashwood P: Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav Immun 23(1): 124-133, 2009.
30. Stamova BS, Tian Y, Nordahl CW, Shen MD, Rogers S, Amaral DG and Sharp FR: Evidence for differential alternative splicing in blood of young boys with autism spectrum disorders. Mol Autism 4(1): 30, 2013.
31. Schopler E, Reichler RJ and Renner BR: The Childhood Autism Rating Scale (CARS). Los Angeles, CA: Western Psychological Services, 1993.
32. Lord C, Risi S, Lambrecht L, Cook EH Jr., Leventhal BL, Di Lavore PC, Pickles A and Rutter M: The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 30(3): 205-223, 2000.
33. Stricker RB and Winger EE: Decreased CD57 lymphocyte subset in patients with chronic Lyme disease. Immunol Lett 76(1): 43-48, 2001.
34. Abo T and Balch C: A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1) J Immunol 127: 1024-1029, 1981.
35. Yoshihara T, Sugihara K, Kizuka Y, Oka S and Asano M: Learning/memory impairment and reduced expression of the HNK-1 carbohydrate in beta4-galactosyltransferase-II-deficient mice. J Biol Chem 284(18): 12550-12561, 2009.
36. + lymphocytes in patients with rheumatoid arthritis. Arthritis Rheuma 36: 608-612, 1993.
37. + T-cell expansion in patients with chronic hepatitis C is associated with liver pathology and poor response to interferon-therapy. J Clin Immunol 24: 258-271, 2004.
38. + T lymphocytes in Mycobacterium tuberculosis-infected patients. Arch Iran Med 9: 53-57, 2006.
39. + lymphocytes after measles infection but not after measles vaccination. J Clin Lab Immunol 53: 1-12, 2005.
40. Stephan JL, Zeller J, Hubert P, Herbelin C, Dayer JM and Prieur AM: Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol 11(4): 451-456, 1993.
41. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A and Grom AA: Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 7(1): R30-37, 2005.
42. Nedvetzki S, Sowinski S, Eagle RA, Harris J, Vely F, Pende D, Trowsdale J, Vivier E, Gordon S and Davis DM: Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood 109(9): 3776-3785, 2007.
43. Bradstreet J, Vogelaar E and Thyer L: Initial Observations of Elevated Alpha-N-Acetylgalactosaminidase Activity Associated with Autism and Observed Reductions from GC Protein-Macrophage Activating Factor Injections. Autism Insights 4: 31-38, 2012.
44. Yamamoto N, Naraparaju VR and Asbell SO: Deglycosylation of serum Vitamin D3-binding protein leads to immuno-suppression in cancer patients. Cancer Res 56(12): 2827-2831, 1996.
45. Siniscalco D, Bradstreet JJ, Cirillo A and Antonucci N: The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages. J Neuroinflammation 11: 78, 2014.
46. Delvin E, Souberbielle JC, Viard JP and Salle B: Role of Vitamin D in acquired immune and autoimmune diseases. Crit Rev Clin Lab Sci 51(4): 232-247, 2014.
47. Wobke TK, Sorg BL and Steinhilber D: Vitamin D in inflammatory diseases. Front Physiol 5: 244, 2014.
48. Ota K, Dambaeva S, Kim MW, Han AR, Fukui A, Gilman-Sachs A, Beaman K and Kwak-Kim J: 1,25-Dihydroxy-Vitamin D3 regulates NK-cell cytotoxicity, cytokine secretion, and degranulation in women with recurrent pregnancy losses. Eur J Immunol 45: 3188-3199, 2015.
49. Moran-Auth Y, Penna-Martinez M, Shoghi F, Ramos-Lopez E and Badenhoop K: Vitamin D status and gene transcription in immune cells. J Steroid Biochem Mol Biol 136: 83-85, 2013.
50. Chen MH, Su TP, Chen YS, Hsu JW, Huang KL, Chang WH, Chen TJ, Pan TL and Bai YM: Is atopy in early childhood a risk factor for ADHD and ASD? A longitudinal study. J Psychosom Res 77(4): 316-321, 2014.
51. Yaghmaie P, Koudelka CW and Simpson E: Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol 131: 428-433, 2013.
52. Matsumura G: Leu7 (HNK-1)-positive cells in peripheral blood and natural killer cell activity in patients with atopic dermatitis. Nihon Hifuka Gakkai Zasshi 100(1): 57-62, 1990.
53. Wehrmann W, Reinhold U, Kukel S, Franke N, Uerlich M and Kreysel HW: Selective alterations in natural killer cell subsets in patients with AD. Int Arch Allergy Appl Immunol 92(3): 318-322, 1990.
54. Katsuta M, Takigawa Y, Kimishima M, Inaoka M, Takahashi R and Shiohara T: NK cells and gamma delta+ T-cells are phenotypically and functionally defective due to preferential apoptosis in patients with atopic dermatitis. J Immunol 176(12): 7736-7744, 2006.
55. Theoharides TC, Angelidou A, Alysandratos KD, Zhang B, Asadi S, Francis K, Toniato E and Kalogeromitros D: Mast cell activation and autism. Biochim Biophys Acta 1822(1): 34-41, 2012.
56. Kurosawa M, Okayama Y, Kobayashi S, Obata K. Rat mast cell granules reacting with a mouse monoclonal antibody M6764 which recognizes the same epitope of a mouse monoclonal antibody HNK-1. Int Arch Allergy Appl Immunol 92(4): 349-355, 1990.
57. Gupta S, Samra D and Agrawal S: Adaptive and Innate Immune Responses in Autism: Rationale for Therapeutic Use of Intravenous Immunoglobulin. J Clin Immunol 30: 90-96, 2010.
58. Hsiao EY and Patterson PH: Activation of the maternal immune system induces endocrine changes in the placenta via IL-6. Brain Behav Immun 25(4): 604-615, 2011.
59. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I and Van de Water J: Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Imm 25(1): 40-45, 2011.
60. Grigorenko EL, Han SS, Yrigollen CM, Leng L, Mizue Y, Anderson GM, Mulder EJ, de Bildt A, Minderaa RB, Volkmar FR, Chang JT and Bucala R: Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics 122(2): e438-e445, 2008.
61. Okada K, Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ, Sekine Y, Suda S, Suzuki K, Sugihara G, Matsuzaki H, Sugiyama T, Kawai M, Minabe Y, Takei N and Mori N: Decreased serum levels of transforming growth factorbeta1 in patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 31(1): 187-190, 2007.
62. + NK-cell subset. Blood 116(19): 3865-3874, 2010.
63. White MJ, Nielsen CM, McGregor RH, Riley EH and Goodier MR: Differential activation of CD57-defined natural killer cell subsets during recall responses to vaccine antigens. Immunology 142(1): 140-150, 2014.
64. Bjorkstrom NK, Lindgren T, Stoltz M, Fauriat C, Braun M, Evander M, Michaelsson J, Malmberg KJ, Klingstrom J, Ahlm C and Ljunggren HG: Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 116(19): 3853-3864, 2010.
65. + population. Lancet 385(1): S45, 2015.
66. Ivarsson MA, Loh L, Marquardt N, Kekalainen E, Berglin L, Bjorkstrom NK, Westgren M, Nixon DF and Michaelsson J: Differentiation and functional regulation of human fetal NK cells. J Clin Invest 123(9): 3889-3901, 2013.
67. Luetke-Eversloh M, Killig M and Romagnani C: Signatures of human NK cell development and terminal differentiation. Front Immunol 4: 499, 2013.
68. Ashwood P, Corbett BA, Kantor A, Schulman H, Van de Water J and Amaral DG: In search of cellular immunophenotypes in the blood of children with autism. PLoS One 6(5): e19299, 2011.
69. Fiumara A, Sciotto A, Barone R, D'Asero G, Munda S, Parano E and Pavone L: Peripheral lymphocyte subsets and other immune aspects in Rett syndrome. Pediatr Neurol 21(3): 619-621, 1999.
70. Antonucci N, Cirillo A and Siniscalco D: Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases. Case Rep Psychiatry 2015: 325061, 2015.
71. Amet L: Identifying and Treating Chronic Infection Issues in Childhood Autism. Antwerp, Belgium. September 12-13, 2015 http://lyme-conference.bbow-apso.be/